Treatment of refractory and relapsed Hodgkin's lymphoma: facts and perspectives.
نویسندگان
چکیده
Aplastic Anemia 11-18 Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppression treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation Anna Locasciulli, Rosi Oneto, Andrea Bacigalupo, Gerard Socié, Elisabeth Korthof, Albert Bekassy, Hubert Schrezenmeier, Jakob Passweg, Monika Führer, on the behalf of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (SAA-WP, BMT)
منابع مشابه
Study of the ratio of Treg/Th1 and Treg/Th2 lymphocytes in Hodgkin's lymphoma patients and its relationship with disease prognosis
Background and purpose: CD4+CD25+FOXP3+ regulatory T cells (CD4+CD25+FOXP3+ Tregs) are a group of T lymphocytes that play an important role in regulating immune system responses by suppressing the activity of other T cells and establishing homeostasis in the immune system. Th1 and Th2 cells are other groups of CD4+ cells that play important functions in inducing inflammatory immune responses. C...
متن کاملTreatment of Newly Diagnosed and Relapsed Hodgkin Lymphoma in Children
Hodgkin lymphoma (HL) accounts for about 10% of all childhood cancers. Five-year survival rates with modern therapies are now approaching >90-95% as a consequence of its significant sensitivity to both chemotherapy and radiation. The current challenge is to determine how much therapy is needed to improve survival and how to adapt treatment to the patient to prevent these long term toxicities. T...
متن کاملTreatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies
Over the last few decades, advances in immunochemotherapy have led to dramatic improvement in the prognosis of non-Hodgkin's lymphoma (NHL). Despite these advances, relapsed and refractory disease represents a major treatment challenge. For both aggressive and indolent subtypes of NHL, there is no standard of care for salvage regimens, with prognosis after relapse remaining relatively poor. Nev...
متن کاملCombination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma.
Twenty-five patients with relapsed or refractory non-Hodgkin's lymphoma were treated by combination chemotherapy with irinotecan hydrochloride (CPT-11) and adriamycin (ADM): CPT-11, 25 mg/m2 on days 1 and 2; ADM, 40 mg/m2 on day 3. Nine (36%) of twenty-five patients achieved CR. Fairly good responses were seen in relapsed B-cell lymphomas (4 of 8 in diffuse large B-cell lymphoma and 2 of 2 in f...
متن کاملDifferent response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma.
BACKGROUND The use of high-dose chemotherapy and autologous stem-cell transplantation in patients with relapsed Hodgkin's lymphoma is supported by two randomized clinical trials but its benefit in patients with primary refractory disease is less clear. Aiming to shed light on this issue, we analyzed and compared the outcomes of patients with relapsed or refractory Hodgkin's lymphoma treated wit...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Haematologica
دوره 92 1 شماره
صفحات -
تاریخ انتشار 2007